VRTX Stock Recent News

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

A 20% drop in Vertex Pharmaceuticals' stock price since I wrote last month was the impetus to make a re-assessment. But the rating has remained unchanged at Hold. This is despite significantly improved Q2 2025 results, seen in both revenue and non-GAAP earnings' growth, with revenues supported by the likes of Alyftrek and Journavx,. However, an unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led to a price plunge.

The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF franchise remains a dominant, reliable growth engine, with new revenue ramps from Casgevy and Journavx set to accelerate diversification. VRTX stock valuation is attractive: forward P/E is favorable versus peers, growth prospects are strong, and insider buying signals management confidence at current prices.

What does it take to qualify as a growth stock? Probably the most important criterion is that the stock must be expected to grow significantly faster than the overall market.

It's been an excellent summer for the broader stock market, with the major indexes hovering around all-time highs and strong earnings from many top companies.

When dark clouds appear on the horizon, it's wise to grab an umbrella, even if the sun is still shining overhead. You'll want to be prepared in case a heavy rain is on the way.

Vertex Pharmaceuticals (VRTX -20.61%) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday.

Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.

Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.

Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.